Roche, the Swiss pharmaceutical giant, has reported an impressive performance in its third-quarter sales, registering a currency-adjusted growth of 9%. This growth has surpassed market expectations, largely driven by an increase in prescriptions for its innovative products, particularly the once-monthly haemophilia treatment, Hemlibra, and the recently launched eye medication, Vabysmo. The company’s group sales reached...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
